Immunotherapy for breast cancer is now being seriously considered, despite past beliefs that this cancer type was non-immunogenic. Immune profiling has been variably associated with outcome, but standard techniques have greatly limited interpretation. These studies examine immune profiling of breast cancer patients using high-sensitivity methods in relation to clinical outcome.

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.